Access
This article is part of Nature's premium content.
Published online 22 July 2008 |
Nature
| doi:10.1038/news.2008.968
Corrected online: 22 July 2008
Corrected online: 22 July 2008
Corrected online: 23 July 2008
News
An offer Genentech can't refuse?
Roche promises to preserve Genentech's independence if it acquires the remaining shares.
On Monday, the Swiss pharmaceutical giant Roche offered US$43.7 billion to acquire the 44% of biotechnology jewel Genentech that it doesn’t currently own.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
This is scary to me- Roche, Invitrogen, sucking up biotech companies like the Blob. We're losing competition and free thought.
I would agree with the above comment. There are so many examples where big pharma gobbles up innovative companies thinking that it is a win-win situation for both. What eventually happens is that neither of them win in the long run. In my opinion a company like Genentech should be left alone... In the past few decades they have lead the way for biotech, and no matter what Roche says, it will eventually kill the true spirit of Genentech.